期刊文献+

丙型肝炎病毒C区截短型基因原核表达载体的构建及在大肠杆菌中的表达 被引量:1

Cloning of the truncated gene of hepatitis C virus core and expression in E.coli
下载PDF
导出
摘要 目的建立稳定表达丙型肝炎病毒(HCV)核心蛋白的原核表达系统,获得高产量的纯化核心蛋白。方法应用多聚酶链反应(PCR),以HCV-H株全长cDNA序列为模板,扩增获得C区羧基端部分缺失的基因片段,克隆入原核表达载体pBVIL1,构建原核表达载体pBVIL1-Ct,转化HB101宿主菌,通过温度诱导表达截短型C蛋白。结果扩增得到目的基因长度为462bp,构建pBVIL1-Ct表达载体,在HB101宿主菌中通过温度诱导获得稳定表达,表达蛋白占菌体总蛋白含量的24%。Western-Blot及ELISA检测证实表达产物可与HCV患者阳性血清发生特异性结合反应。结论羧基端部分缺失的HCV C区基因片段可在大肠杆菌中稳定表达并具有良好的反应原性。 Objective To construct a steady expression system of HCV truncated Core gene in E. coll. Methods The cDNA sequence encoding truncated HCV Core gene which lacked parts of the carboxyl-terminal were amplified by PCR and inserted into plasmid pBVIL1; the resulting expression vector was transformed into HB101 E. coli and the protein was expressed by temperature induction. Results The length of amplified truncated Core gene was 462 bp; the yield of truncated Core protein produced in pBVIL1 was 24% of the total proteins. The protein produced was detected by SDS-PAGE, western blot and ELISA. The results showed specific immunoreactivity with serum from patients with hepatitis C in western blot and ELISA assay. Conclusion Truncated HCV Core gene which lacked parts of the carboxyl-terminal was expressed in E. coli and exhibited immunogenicity.
出处 《西安交通大学学报(医学版)》 CAS CSCD 北大核心 2005年第4期320-322,326,共4页 Journal of Xi’an Jiaotong University(Medical Sciences)
关键词 丙型肝炎病毒(HCV) 核心蛋白 基因表达 大肠杆菌 hepatitis C virus(HCV) core protein gene expression E. coli
  • 相关文献

参考文献7

二级参考文献42

  • 1Wen Jie Dai,Hong Chi Jiang Second Department of General Surgery, the First Clinical School, Harbin Medical University, Harbin 150001, Heilongjiang Province, China.Advances in gene therapy of liver cirrhosis: a review[J].World Journal of Gastroenterology,2001,7(1):1-8. 被引量:34
  • 2Huang F,Zhao GZ,Li Y.HCV genotypes in hepatitis C patients and their clinical significances[J].World Journal of Gastroenterology,1999,5(6):547-549. 被引量:23
  • 3金冬雁.分子克隆(实验指南)[M].北京:科学出版社,1992..
  • 4[1]Harada S, Watanabe Y, La Monic N, et al. Expression of processed core protein of hepatitis C virus in mammalian cells[J].J Virol,1991,65:3015-3021.
  • 5[2]Santolini E, Migliaccio G, La Monica N, et al. Biosynthesis and biochemical properties of the hepatitis C virus core protein[J].J VIROL,1994,68:3631-3641.
  • 6[3]Lo S-Y, Selby M, Tong M, et al. Comparative studies of the core gene products of two different hepatitis C virus isolates: Two alternative forms determined by a single amino acid substitution[J].Virology,1994,199:124-131.
  • 7[4]Liu Q, Tackney C, Bhat RA, et al. Regulated processing of hepatitis C virus core protein is linked to subcellular localization[J].J VIROL,1997,71:657-662.
  • 8[5]Yasui K, Wakita T, Tsukiyama-Kohara K, et al. The native form and maturation process of hepatitis C virus core protein [J].J Vorol,1998,72:6048-6055.
  • 9[6]Suzuki R, Matsuura Y, Suzuki T, et al. Nuclear localization of the truncated hepatitis C virus core protein with its hydrophobic C terminus deleted[J],J Gen Virol,1995,76:53-61.
  • 10[7]Chang S-C, Yen J-H, Kang H-Y, et al. Nuclear localization signals in the core protein of hepatitis C virus. Biochem Biophys Res Commun [J],1994,205:1284-1290.

共引文献72

同被引文献12

  • 1Lavaissiere L, Jia S, Nishiyama M, et al, Overexpression of human aspartyl (asparaginyl) β-hydroxylase in hepatocellular carcinoma and cholangiocarcinoma. J Clin Invest, 1996, 98(6): 1313-1323.
  • 2Jones LR, Zhang L, Sanborn K, et al. Purification, primary structure, and immunological characterization of the 26-kDa calsequestrin binding protein (junctin) from cardiac junctional sarcoplasmic reticulum. J Biolog Chemis, 1995, 270(51): 30787-30796.
  • 3Ince N, de la Monte SM, and Wands JR. Overexpression of human aspartyl (asparaginyl) b-hydroxylase is associated with malignant transformation. Cancer Res, 2000, 60(5): 1261-1266.
  • 4Maeda T, Sepe P, Lahousse S, et al. Antisense oligodeoxynucleotides directed against aspartyl (asparaginyJ) β-hydroxylase suppress migration of cholangiocarcinoma cells. J Hepatol, 2003, 38(5): 615-622.
  • 5Takashi M, Ken-ichi T, Shin-ichi A, et al. Clinicopathological correlates of aspartyl (asparaginyl)β-hydroxylase over-expression in cholangiocarcinoma. Cancer Detect Prevent, 2004, 28(5): 313-318.
  • 6Feldmann G, Nattermann J, Nischalke HD, et al. Detection of human aspartyl (asparaginyl) β-hydroxylase and homeobox B7 mRNA in brush cytology specimens from patients with bile duct cancer. Endoscopy, 2006, 38(6): 604-609.
  • 7Palumbo KS, Wands JR, Safran H, et al. Human aspartyl (asparaginyl) β-hydroxylase monoclonal antibodies: potential biomarkers for pancreatic carcinoma. Pancreas, 2002, 25(1): 39-44.
  • 8De la Montel SM, Tamakil S, Cantarini MC, et al. Aspartyl- (asparaginyl)-β-hydroxylase regulates hepatocellular carcinoma invasiveness. J Hepatol, 2006, 44(5): 971-983.
  • 9Lee SW, Cho JH, Sung YC. Optimal induction of hepatitis C virus envelope-specific immunity by bicistronic plasmid DNA inoculation with the granulocyte-macrophage colony-stimulating factor gene. J Virol, 1998, 72(10): 8430-8436.
  • 10Dinchuk JE, Henderson NL, Burn TC, et al. Aspartyl beta-hydroxylase (Asph) and an evolutionarily conserved isoform of Asph missing the catalytic domain share exons with junctin. J Biol Chem, 2000, 275(50): 39543-39554.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部